Ureteropelvic Junction Obstruction

Slides:

Advertisements

Similar presentations

Pascal Rischmann European Urology Supplements

Advertisements

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Achieving the Total Approach in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia (LUTS/BPH) Management Michael O’Leary European Urology Supplements

2004 World Health Organization Classification of the Noninvasive Urothelial Neoplasms: Inherent Problems and Clinical Reflections Rodolfo Montironi,

Management of Acute and Chronic Retention in Men

Olivier Traxer European Urology Supplements

The Role of Residual Tumor Resection in Patients with Metastatic Renal Cell Carcinoma and Partial Remission following Immunochemotherapy Olaf A. Brinkmann,

Bladder Cancer: Management and Future Directions

Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?

Martin C. Michel European Urology Supplements

Treatment of Advanced and Metastatic Renal Cancer: A Revolution?

Bladder Cancer: A Major Public Health Issue

What is New in Bladder Cancer Diagnosis and Management?

Back to the Future: Introduction and Conclusions

Volume 70, Issue 3, Pages (September 2016)

A Novel Treatment of Premature Ejaculation

Treatment of Symptomatic Benign Prostatic Hyperplasia: Current and Future Clinical Practice in Europe – What is Really Happening? Bob Djavan European.

Counselling the Prostate Cancer Patient

Laurent Boccon-Gibod European Urology Supplements

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

An Update of Current Practice in Hypospadias Surgery

Richard C. Harkaway European Urology Supplements

Tyrosine Kinase Inhibitors in Clinical Practice: Patient Selection

Mammalian Target of Rapamycin Inhibitors in Clinical Practice: Case Reports of Everolimus in Renal Cell Carcinoma Sergio Bracarda, Alain Ravaud, Marino.

Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy Bertrand Tombal, Richard Berges European Urology.

Tamsulosin Oral Controlled Absorption System (OCAS) in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH):

The Importance of Testosterone Control in Prostate Cancer

Jacques Irani European Urology Supplements

Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice Claus Roehrborn European Urology.

Neal Shore European Urology Supplements

Impact of Tamsulosin OCAS on Energy of Patients with LUTS/BPH

Long-Term Hormonal Therapy: Who Would Benefit?

Laparoscopic Ureteroureterostomy for Retrocaval Ureter

Sergio Bracarda European Urology Supplements

Pharmacotherapy in Stress and Mixed Incontinence

What are the Data on 5α-Reductase Inhibitor Treatment of Benign Prostatic Hyperplasia from Everyday Practice? François Desgrandchamps European Urology.

Christian Stief European Urology Supplements

Bisphosphonates Can Prevent Skeletal Complications of Malignant Bone Disease from Prostate Cancer and Renal Cell Carcinoma Fred Saad European Urology.

New Trends in Managing the Prostate Cancer Patient

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Emmanuel Chartier-Kastler, Kate Davidson European Urology Supplements

A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study John Fitzpatrick European.

Who Forms Stones and Why?

Martin Michel, Jean de la Rosette European Urology Supplements

How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia? Vincenzo Mirone

Retrocaval Ureter—Magnetic Resonance Appearances

The European Online Sexual Survey (EOSS): Pan-European Perspectives on the Impact of Premature Ejaculation and Treatment-Seeking Behavior John Dean

Richard Berges European Urology Supplements

Improving Flexibility and Quality of Life for Your Patients: A Must?

The Burden of Stress Urinary Incontinence

Profile of Silodosin European Urology Supplements

Robotic Cystectomy Versus Open Cystectomy: Are We There Yet?

New Concepts in Epidemiology of Lower Urinary Tract Symptoms in Men

Epidemiology, Pathogenesis, and Pathophysiology of Urolithiasis

The Increasing Responsibility of the Urologist in Maintaining Bone Health in Prostate Cancer Patients Kurt Miller European Urology Supplements Volume.

Prognostic Factors in Non–Muscle-Invasive Bladder Tumors

Testim® Gel: Review of Clinical Data

Beyond Skeletal-Related Events

Treatment Options in Prostate Cancer Once Primary Therapy Fails

Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer Sten Holmäng European Urology.

Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma Jan Roigas European Urology Supplements Volume.

Joaquim Bellmunt European Urology Supplements

Classification of Mixed Incontinence

The Impact of Premature Ejaculation on Partners and Relationships

Diagnosis and Management of Cryptorchidism

New Research Findings on Clinical Benefits of Bisphosphonates in Patients With Advanced Prostate Cancer Noel W. Clarke European Urology Supplements

Jan Roigas European Urology Supplements

Volume 51, Issue 5, Pages (May 2007)

Introduction European Urology Supplements

Presentation transcript:

Ureteropelvic Junction Obstruction Hashim Hashim, Christopher R.J. Woodhouse European Urology Supplements Volume 11, Issue 2, Pages 25-32 (April 2012) DOI: 10.1016/j.eursup.2012.01.004 Copyright © 2012 European Association of Urology Terms and Conditions

Fig. 1 Type 1 renogram. European Urology Supplements 2012 11, 25-32DOI: (10.1016/j.eursup.2012.01.004) Copyright © 2012 European Association of Urology Terms and Conditions

Fig. 2 Type 2 renogram of left kidney (40mg frusemide administered intravenously at 15min). European Urology Supplements 2012 11, 25-32DOI: (10.1016/j.eursup.2012.01.004) Copyright © 2012 European Association of Urology Terms and Conditions

Fig. 3 Type 3a renogram bilaterally (5mg frusemide administered intravenously at 15min). European Urology Supplements 2012 11, 25-32DOI: (10.1016/j.eursup.2012.01.004) Copyright © 2012 European Association of Urology Terms and Conditions

Fig. 4 Outcome of treated patients with ureteropelvic junction obstruction (UPJO) based on diethylenetriamine penta-acetic acid (DTPA) results. APD=anteroposterior diameter. European Urology Supplements 2012 11, 25-32DOI: (10.1016/j.eursup.2012.01.004) Copyright © 2012 European Association of Urology Terms and Conditions

Fig. 5 Suggested algorithm for the treatment of ureteropelvic junction obstruction. APD=anteroposterior diameter; DMSA=dimercaptosuccinic acid; MAG3=mercaptoacetyltriglycine; MCUG=micturating cystourethrogram; SFU=Society of Fetal Ultrasound; USS=ultrasonographic scan. European Urology Supplements 2012 11, 25-32DOI: (10.1016/j.eursup.2012.01.004) Copyright © 2012 European Association of Urology Terms and Conditions